Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease
Top Cited Papers
Open Access
- 16 May 2000
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (11) , 6037-6042
- https://doi.org/10.1073/pnas.090106797
Abstract
The major known genetic risk for Alzheimer9s disease (AD), apolipoprotein E-4 (APOE-4), is associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in patients with a clinical diagnosis of AD. To determine cognitive and metabolic decline patterns according to genetic risk, we investigated cerebral metabolic rates by using positron emission tomography in middle-aged and older nondemented persons with normal memory performance. A single copy of the APOE-4 allele was associated with lowered inferior parietal, lateral temporal, and posterior cingulate metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. For the 20 nondemented subjects followed longitudinally, memory performance scores did not decline significantly, but cortical metabolic rates did. In APOE-4 carriers, a 4% left posterior cingulate metabolic decline was observed, and inferior parietal and lateral temporal regions demonstrated the greatest magnitude (5%) of metabolic decline after 2 years. These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments.Keywords
This publication has 52 references indexed in Scilit:
- Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PETBrain, 1999
- Normal and pathological aging - findings of positron-emission-tomographyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1998
- Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's diseaseAnnals of Neurology, 1998
- The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled TrialDementia and Geriatric Cognitive Disorders, 1996
- Apolipoprotein E and cognitive change in an elderly populationAnnals of Neurology, 1996
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993
- Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementiaNeurobiology of Aging, 1993
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- Age‐associated memory impairment: Proposed diagnostic criteria and measures of clinical change — report of a national institute of mental health work groupDevelopmental Neuropsychology, 1986
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984